CNS Therapeutics Market
Central Nervous System (CNS) Therapeutics Market Analysis by Segment (Pain Management CNS Therapeutics, Anti-psychotics, Anti-depressants, Anti-epilepsy, Anti-Alzheimer’s, Anti-Parkinson’s) And by Region - Global Forecast 2022 to 2026
Analysis of CNS Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Central Nervous System (CNS) Therapeutics Market Outlook (2022 to 2026)
The CNS therapeutics market stands at a valuation of US$ 116.7 Billion in 2022, and is expected to reach US$ 142.1 Billion by the end of 2026. CNS drug sales are projected to rise at a steady CAGR of 4.9% from 2022 to 2026.
Revenue from CNS drug sales in the United States is projected to be valued at US$ 36.1 Bn by the end of 2026.
| Report Attributes | Details |
|---|---|
| CNS Therapeutics Market Size (2022) | US$ 116.7 Billion |
| Projected Year Value (2026F) | US$ 142.1 Billion |
| Global Market Growth Rate (2022 to 2026) | 4.9% CAGR |
| United States Market Value (2026) | US$ 36.1 Billion |
| Key Companies Profiled | Allergan Plc.; AbbVie Inc.; Alkermes Plc.; AstraZeneca Plc.; Bristol-Myers Squibb; Eisai Co. Ltd.; Eli Lilly and Co.; Endo Pharmaceuticals Inc.; F. Hoffman-La Roche Ltd.; GlaxoSmithKline Plc.; H. Lundbeck A/S; Janssen Pharmaceuticals Inc.; Merck & Co. Inc.; Neurocrine Biosciences Inc.; Novartis AG; Otsuka Pharmaceutical Co. Ltd.; Pfizer Inc.; Purdue Pharma L.P.; Sanofi; Shire Plc.; Sumitomo Dainippon Pharma Co. Ltd.; Takeda Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; UCB Group |
CNS drug companies are focusing on launching new drugs to expand their product portfolio and increase their sales amidst rising demand for CNS therapeutics on a global level. Rising prevalence of neurodegenerative diseases will also propel demand for brain therapeutics on a global scale.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
CNS Therapeutics Demand Analysis (2017 to 2021) in Comparison to Market Growth Forecasts (2022 to 2026)
Disorders and diseases related to the central nervous system (CNS) have increased in prevalence over the past few years and this trend has largely influenced the central nervous system therapeutics market potential.
CNS therapies are expected to gain popularity as their efficacy in the treatment of multiple CNS-related conditions is proved. Brain therapeutics are expected to see high demand owing to rising prevalence of neurological disorders.
Rising prevalence of CNS diseases, increasing healthcare expenditure, and rising research activities in CNS neuroscience and therapeutics are prime factors that influence the central nervous system (CNS) therapeutics market potential over the coming years.
Rising awareness regarding neurological disorders, increasing instances of lifestyle-related CNS disorders, and increasing levels of stress among the general population are other factors that guide the consumption of CNS therapeutics.
Regulatory bodies take more time to evaluate and approve CNS drugs than non-CNS drugs, and this is due to the complex nature of these drugs, high costs of CNS medications, and increasing instances of the side effects associated with the use of these drugs.
Demand for CNS therapeutics is projected to rise at a CAGR of 4.9% from 2022 to 2026.
How are Lifestyle Changes Affecting CNS Therapeutics Market Potential?
“Poor Lifestyle Choices Increasing Risk of Neurodegenerative Disorders”
Lifestyle habits have changed drastically over the past few years and this has largely affected the overall health trends of the general population and given rise to multiple diseases owing to poor lifestyle choices.
CNS disorders have also increased in prevalence due to increased stress in the lifestyle of the general population. The world has also seen a hike in instances of Alzheimer’s and Parkinson’s diseases.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How are Regulatory Approvals Restricting CNS Therapeutics Demand?
“Longer than Usual Time Taken to Approve CNS Drugs Hampering Market Growth”
All drugs have to undergo a regulatory process to get approval for commercialization and general use. Regulatory bodies take longer time to approve CNS drugs than non-CNS drugs, which increases the time taken for these drug to reach the markets and increases the risks for CNS drug companies.
This factor is expected to lead several manufacturers to abstain from investing in CNS drug research and development owing to rising risks involved.
Will Cost of Drugs Influence CNS Therapeutics Market Potential?
“High Costs of CNS Drugs to Negatively Impact Sales Growth”
CNS drugs involve extensive research and development which incurs huge costs to CNS drug manufacturers and hence increases the pricing of the end product. Moreover, longer approval times increase the risk of investment, and hence CNS drug vendors price their products at high costs to recover their spending and keep the business running.
All of these factors adversely affect patients who purchase these CNS drugs and high costs even hamper sales of CNS drugs in regions with low spending potential.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Which Region Should CNS Drug Vendors Keep an Eye Out For?
“North America to Emerge as Highly Rewarding Market for CNS Therapeutics”
The market for CNS therapeutics in North America is anticipated to be a highly lucrative market over the forecast period. The increasing prevalence of CNS diseases and the rising geriatric population are projected to be major factors driving CNS therapeutics market growth in this region.
The United States and Canada are anticipated to be prime markets that CNS drug companies should focus on in this region. Increasing investments from the government and rising awareness of CNS disorders will also favor CNS therapeutics consumption in the aforementioned countries.
Increasing focus on the development of healthcare infrastructure in regions of South Asia and East Asia is expected to provide rewarding opportunities for top CNS drug pharma companies. Increasing focus on CNS pharmacology by pharmaceutical companies and governments is also expected to favor CNS therapeutics market potential in the aforementioned regions.
Shipments of CNS drugs in China are projected to progress at a CAGR of 8% from 2022 to 2026.
Country-wise Insights
What is the Outlook for the U.S. CNS Therapeutics Industry?
“Supportive Government Initiatives to Favor Demand for CNS Therapies”
Focus on mental health and CNS disorders has substantially increased in the U.S. over the past years and is projected to follow a similar trend through 2026.
Increasing geriatric population, rising instances of Alzheimer’s, Parkinson’s, increasing research activity, and rising government investments to increase awareness about CNS diseases are major factors that drive CNS therapeutics market potential in the U.S.
The market in the U.S. is expected to be worth US$ 36.1 Bn by the end of the forecast period.
Category-wise Insights
What Impact Will Increasing Instances of Alzheimer’s Have on Market Growth?
“Anti-Alzheimer’s Drugs to See High Demand Going Forward”
The incidence of Alzheimer’s has seen a substantial rise over the past few years and is expected to continue this rise over the forecast period as well. Awareness of the disease is also expected to increase with efforts from government and pharmaceutical companies.
These factors will increase the demand for anti-Alzheimer’s drugs and other brain therapeutics across the world through 2026.
How Did the CNS Therapeutics Market Perform During the Pandemic?
Emergence of COVID-19 led to major changes in healthcare trends across the world and had to a negative impact on the CNS therapeutics market. Focus was completely on the treatment and management of coronavirus infections and this led to negligence towards other diseases and hence resulted in a slowdown of CNS drug demand.
The CNS therapeutics market is projected to rise at a steady pace in the post-pandemic era as coronavirus infections recede and focus on other healthcare conditions returns back to normal. The increasing geriatric population will be mostly at risk of being affected by CNS diseases and will drive the consumption of CNS therapeutics through 2026.
Competitive Landscape
CNS drug manufacturers are increasing their investments in research and development activities in order to fast-track the development of novel treatment drugs.
Increasing CNS pharmaceutical clinical trials to test the efficacy of drugs will also play a crucial role in the launch of new drugs.
- In April 2021, two leading names in the CNS therapeutics market - Otsuka Pharmaceuticals Co. Ltd. and H. Lundbeck A/S - announced the continuation of recruitment of new patients for their phase III clinical trials aimed at the treatment of Alzheimer’s dementia. The clinical trial focuses on the use of brexpiprazole for the treatment of the aforementioned medical condition.
Key Segments Covered in CNS Therapeutics Industry Research
-
By Segment :
- Pain Management CNS Therapeutics
- Anti-psychotics
- Anti-depressants
- Anti-epilepsy
- Anti-Alzheimer’s
- Anti-Parkinson’s
- Other Segments
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Outlook, by Region
- 4. Market Trend Analysis, 2022 to 2026
- 5. Global Market Analysis and Forecast, by Segment, 2022 to 2026
- 5.1. Pain Management
- 5.2. Anti-psychotics
- 5.3. Anti-depressants
- 5.4. Anti-epilepsy
- 5.5. Anti-Alzheimer’s
- 5.6. Anti-Parkinson’s
- 5.7. Other Segments
- 6. Global Market Analysis and Forecast, by Region, 2022 to 2026
- 6.1. North America
- 6.2. Europe
- 6.3. Asia Pacific
- 6.4. Middle East & Africa
- 6.5. Latin America
- 7. North America Market Analysis and Forecast, 2022 to 2026
- 8. Europe Market Analysis and Forecast, 2022 to 2026
- 9. Asia Pacific Market Analysis and Forecast, 2022 to 2026
- 10. Latin America Market Analysis and Forecast, 2022 to 2026
- 11. Middle East & Africa Market Analysis and Forecast, 2022 to 2026
- 12. Competition Landscape
- 12.1. Segment Mapping
- 12.2. AbbVie Inc.
- 12.3. Alkermes Plc.
- 12.4. AstraZeneca Plc.
- 12.5. Bristol-Myers Squibb
- 12.6. Eisai Co. Ltd.
- 12.7. Eli Lilly and Co.
- 12.8. Endo Pharmaceuticals Inc.
- 12.9. F. Hoffman-La Roche Ltd.
- 12.10. GlaxoSmithKline Plc.
- 12.11. H. Lundbeck A/S
- 12.12. Janssen Pharmaceuticals Inc.
- 12.13. Merck & Co. Inc.
- 12.14. Neurocrine Biosciences Inc.
- 12.15. Novartis AG
- 12.16. Otsuka Pharmaceutical Co. Ltd.
- 12.17. Pfizer Inc.
- 12.18. Purdue Pharma L.P.
- 12.19. Sanofi
- 12.20. Shire Plc.
- 12.21. Sumitomo Dainippon Pharma Co. Ltd.
- 12.22. Takeda Pharmaceutical Co. Ltd.
- 12.23. Teva Pharmaceutical Industries Ltd.
- 12.24. UCB Group
- 13. Assumptions & Acronyms Used
- 14. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 2: Global Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 3: Global Market Value (Mn) Analysis, 2022 to 2026
Table 4: Global Market Value (Mn) Analysis, 2022 to 2026
Table 5: Global Market Value (Mn) Forecast, by Region, 2022 to 2026
Table 6: Global Market Value (Mn) Forecast, by Region, 2022 to 2026
Table 7: North America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 8: North America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 9: North America Market Value (Mn) Analysis, 2022 to 2026
Table 10: North America Market Value (Mn) Analysis, 2022 to 2026
Table 11: North America Market Value (Mn) Forecast, by Country, 2022 to 2026
Table 12: North America Market Value (Mn) Forecast, by Country, 2022 to 2026
Table 13: U.S. Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 14: U.S. Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 15: U.S. Market Value (Mn) Analysis, 2022 to 2026
Table 16: U.S. Market Value (Mn) Analysis, 2022 to 2026
Table 17: Canada Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 18: Canada Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 19: Canada Market Value (Mn) Analysis, 2022 to 2026
Table 20: Canada Market Value (Mn) Analysis, 2022 to 2026
Table 21: Europe Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 22: Europe Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 23: Europe Market Value (Mn) Analysis, 2022 to 2026
Table 24: Europe Market Value (Mn) Analysis, 2022 to 2026
Table 25: Europe Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 26: Europe Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 27: Germany Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 28: Germany Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 29: Germany Market Value (Mn) Analysis, 2022 to 2026
Table 30: Germany Market Value (Mn) Analysis, 2022 to 2026
Table 31: U.K. Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 32: U.K. Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 33: U.K. Market Value (Mn) Analysis, 2022 to 2026
Table 34: U.K. Market Value (Mn) Analysis, 2022 to 2026
Table 35: France Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 36: France Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 37: France Market Value (Mn) Analysis, 2022 to 2026
Table 38: France Market Value (Mn) Analysis, 2022 to 2026
Table 39: Italy Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 40: Italy Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 41: Italy Market Value (Mn) Analysis, 2022 to 2026
Table 42: Italy Market Value (Mn) Analysis, 2022 to 2026
Table 43: Spain Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 44: Spain Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 45: Spain Market Value (Mn) Analysis, 2022 to 2026
Table 46: Spain Market Value (Mn) Analysis, 2022 to 2026
Table 47: Russia & CIS Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 48: Russia & CIS Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 49: Russia & CIS Market Value (Mn) Analysis, 2022 to 2026
Table 50: Russia & CIS Market Value (Mn) Analysis, 2022 to 2026
Table 51: Rest of Europe Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 52: Rest of Europe Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 53: Rest of Europe Market Value (Mn) Analysis, 2022 to 2026
Table 54: Rest of Europe Market Value (Mn) Analysis, 2022 to 2026
Table 55: Asia Pacific Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 56: Asia Pacific Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 57: Asia Pacific Market Value (Mn) Analysis, 2022 to 2026
Table 58: Asia Pacific Market Value (Mn) Analysis, 2022 to 2026
Table 59: Asia Pacific Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 60: Asia Pacific Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 61: China Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 62: China Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 63: China Market Value (Mn) Analysis, 2022 to 2026
Table 64: China Market Value (Mn) Analysis, 2022 to 2026
Table 65: Japan Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 66: Japan Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 67: Japan Market Value (Mn) Analysis, 2022 to 2026
Table 68: Japan Market Value (Mn) Analysis, 2022 to 2026
Table 69: India Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 70: India Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 71: India Market Value (Mn) Analysis, 2022 to 2026
Table 72: India Market Value (Mn) Analysis, 2022 to 2026
Table 73: ASEAN Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 74: ASEAN Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 75: ASEAN Market Value (Mn) Analysis, 2022 to 2026
Table 76: ASEAN Market Value (Mn) Analysis, 2022 to 2026
Table 77: Rest of Asia Pacific Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 78: Rest of Asia Pacific Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 79: Rest of Asia Pacific Market Value (Mn) Analysis, 2022 to 2026
Table 80: Rest of Asia Pacific Market Value (Mn) Analysis, 2022 to 2026
Table 81: Latin America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 82: Latin America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 83: Latin America Market Value (Mn) Analysis, 2022 to 2026
Table 84: Latin America Market Value (Mn) Analysis, 2022 to 2026
Table 85: Latin America Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 86: Latin America Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 87: Brazil Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 88: Brazil Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 89: Brazil Market Value (Mn) Analysis, 2022 to 2026
Table 90: Brazil Market Value (Mn) Analysis, 2022 to 2026
Table 91: Mexico Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 92: Mexico Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 93: Mexico Market Value (Mn) Analysis, 2022 to 2026
Table 94: Mexico Market Value (Mn) Analysis, 2022 to 2026
Table 95: Rest of Latin America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 96: Rest of Latin America Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 97: Rest of Latin America Market Value (Mn) Analysis, 2022 to 2026
Table 98: Rest of Latin America Market Value (Mn) Analysis, 2022 to 2026
Table 99: Middle East & Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 100: Middle East & Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 101: Middle East & Africa Market Value (Mn) Analysis, 2022 to 2026
Table 102: Middle East & Africa Market Value (Mn) Analysis, 2022 to 2026
Table 103: Middle East & Africa Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 104: Middle East & Africa Market Value (Mn) Forecast, by Country and Sub-region, 2022 to 2026
Table 105: GCC Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 106: GCC Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 107: GCC Market Value (Mn) Analysis, 2022 to 2026
Table 108: GCC Market Value (Mn) Analysis, 2022 to 2026
Table 109: South Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 110: South Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 111: South Africa Market Value (Mn) Analysis, 2022 to 2026
Table 112: South Africa Market Value (Mn) Analysis, 2022 to 2026
Table 113: Rest of Middle East & Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 114: Rest of Middle East & Africa Market Value (Mn) Forecast, by Segment, 2022 to 2026
Table 115: Rest of Middle East & Africa Market Value (Mn) Analysis, 2022 to 2026
Table 116: Rest of Middle East & Africa Market Value (Mn) Analysis, 2022 to 2026
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Price Trend, by Region, 2022 to 2026 (US$/Ton)
Figure 2: Global Market Value Share, by Segment, 2022 and 2026
Figure 3: Global Market Attractiveness, by Segment
Figure 4: Global Market Value Share, Analysis, 2022 and 2026
Figure 5: Global Market Attractiveness, Analysis
Figure 6: Global Market Value Share, by Region, 2022 and 2026
Figure 7: Global Market Attractiveness, by Region
Figure 8: North America Market Value Share, by Segment, 2022 and 2026
Figure 9: North America Market Attractiveness, by Segment
Figure 10: North America Market Value Share, Analysis, 2022 and 2026
Figure 11: North America Market Attractiveness, Analysis
Figure 12: North America Market Value Share, by Country, 2022 and 2026
Figure 13: North America Market Attractiveness, by Country
Figure 14: Europe Market Value Share, by Segment, 2022 and 2026
Figure 15: Europe Market Attractiveness, by Segment
Figure 16: Europe Market Value Share, Analysis, 2022 and 2026
Figure 17: Europe Market Attractiveness, Analysis
Figure 18: Europe Market Value Share, by Country and Sub-region, 2022 and 2026
Figure 19: Europe Market Attractiveness, by Country and Sub-region
Figure 20: Asia Pacific Market Value Share, by Segment, 2022 and 2026
Figure 21: Asia Pacific Market Attractiveness, by Segment
Figure 22: Asia Pacific Market Value Share, Analysis, 2022 and 2026
Figure 23: Asia Pacific Market Attractiveness, Analysis
Figure 24: Asia Pacific Market Value Share, by Country and Sub-region, 2022 and 2026
Figure 25: Asia Pacific Market Attractiveness, by Country and Sub-region
Figure 26: Latin America Market Value Share, by Segment, 2022 and 2026
Figure 27: Latin America Market Attractiveness, by Segment
Figure 28: Latin America Market Value Share, Analysis, 2022 and 2026
Figure 29: Latin America Market Attractiveness, Analysis
Figure 30: Latin America Market Value Share, by Country and Sub-region, 2022 and 2026
Figure 31: Latin America Market Attractiveness, by Country and Sub-region
Figure 32: Middle East & Africa Market Value Share, by Segment, 2022 and 2026
Figure 33: Middle East & Africa Market Attractiveness, by Segment
Figure 34: Middle East & Africa Market Value Share, Analysis, 2022 and 2026
Figure 35: Middle East & Africa Market Attractiveness, Analysis
Figure 36: Middle East & Africa Market Value Share, by Country and Sub-region, 2022 and 2026
Figure 37: Middle East & Africa Market Attractiveness, by Country and Sub-region
Figure 38: Global Market Share Analysis, by Company, 2020
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the CNS therapeutics market projected to be worth by 2026?
Consumption of CNS therapeutics is predicted to account for US$ 142.1 Billion by 2026.
At what pace is the CNS therapeutics market anticipated to rise?
From 2022 to 2026, the market for CNS therapeutics is anticipated to evolve at a CAGR 4.9%.
Which is the largest regional market for CNS therapeutics?
The U.S. is largest market for CNS therapeutics, and is anticipated to hold a market value of US$ 36.1 Bn by the end of 2026.
At what CAGR is demand for CNS therapeutics anticipated to rise in China?
Over the forecast period, the China CNS therapeutics market is projected to surge ahead at CAGR of 8%.
What valuation does the CNS therapeutics market currently enjoy?
In 2022, the global CNS therapeutics market stands at a valuation US$ 116.7 Bn.
Which top CNS pharma companies are mentioned in this research?
Top CNS therapeutic drug manufacturers are AbbVie Inc., Alkermes Plc., AstraZeneca Plc., Bristol-Myers Squibb, Eisai Co. Ltd., Eli Lilly and Co., Endo Pharmaceuticals Inc., F. Hoffman-La Roche Ltd., GlaxoSmithKline Plc., H. Lundbeck A/S, Janssen Pharmaceu
CNS Therapeutics Market